Search Press Releases

 Search

Statement of the COPD Foundation on the Death of Congressman John Lewis

July 18, 2020

Congressman John Lewis

Saturday, July 18, 2020 – Late last evening, America lost one of its greatest civil rights leaders, Congressman John Lewis. A tireless advocate for racial and social justice, he stepped forward to serve those who faced many challenges including people with COPD.

Congressman Lewis was a founding co-chair of the Congressional COPD Caucus where he contributed his voice, his passion, and his power to our community’s needs. In November 2019, the Foundation honored his longstanding commitment to our mission with the Edna Shattuck Advocacy Award.

"We are deeply saddened to learn the news of Congressman Lewis’ death," commented Dr. James Crapo, the COPD Foundation’s Chairman of the Board and Interim CEO. "We extend our heartfelt sympathies to his family and loved ones and want them to know he will be sorely missed by our community among so many who benefitted from his leadership."

Read More

COPD Foundation Announces New Appointment

July 07, 2020

Appointment Reflects Renewed Focus on Clinical Research and Patient Community Education

Washington, DC – July 7, 2020 - The COPD Foundation announces the appointment of James D. Crapo, MD, to Chairman of the Board of Directors and as its interim Chief Executive Officer.

Dr. Crapo has been closely affiliated with the COPD Foundation since its inception and was asked to join the COPD Foundation’s Board of Directors in 2007. In addition, Dr. Crapo worked closely with Founder John W. Walsh on multiple initiatives. Dr. Crapo has served on the Executive, Medical and Scientific Advisory and Development committees of the COPD Foundation.

He is Professor of Medicine at National Jewish Health Denver, Manager of BioMimetix JV, LLC, and Principal Investigator for the COPDGene clinical epidemiology project, one of the largest studies ever to investigate the underlying genetic factors of chronic obstructive pulmonary disease. From 1992-1993, Dr. Crapo was President of the American Thoracic Society. He also served as President of the Fleischner Society between 2004 and 2005. For six years beginning in 2003, Dr. Crapo served as a member of the Clean Air Scientific Advisory Committee of the U.S. Environmental Protection Agency.

Read More

Grifols is Collaborating with the U.S. Government to Produce a COVID-19 Treatment

March 26, 2020

WASHINGTON, DC—March 27, 2020 - In this time of great need, many companies are working around the clock to find solutions to the COVID-19 crisis. One of the COPD Foundation’s valued partners, Grifols, has announced the formation of a partnership with several U.S. government agencies to undertake clinical studies to determine if plasma from convalescent COVID-19 patients can lead to a potential treatment for the disease.

This innovative private-public partnership has the ability to expedite the development process and hopefully bring effective treatments to the market in a timely manner. This is just one of several projects Grifols is working on that will help nations around the world address this pandemic.

You can read the official Grifols statement on their partnership by clicking here.

Read More

Leading Medical Journal Publishes COPD Assessment Test (CAT) Summary Data

December 20, 2019

The COPD Foundation is pleased to announce the publication of exciting data about the COPD Assessment Test (CAT) in the American Journal of Respiratory and Critical Care, a scientific journal published by the American Thoracic Society.

The manuscript, entitled "Clinical Development and Research Applications of the COPD Assessment Test (CAT)", was a result of the COPD Biomarker Qualification Consortium’s (CBQC) work. It highlights the importance of the CAT as a clinical outcome assessment tool as beneficial both in clinical practice and in research applications.

“This achievement demonstrates the power of patient-led collaborations in paving the road to improved disease management,” said Ruth Tal-Singer, Scientific Strategy Advisor at the COPD Foundation and former Industry Chair of the CBQC.

The CAT was developed by a multidisciplinary group of international experts in COPD as a short, easy-to-use (paper or digital) tool for patients, researchers and healthcar1e providers to assess symptoms and impact of the disease as described on the CAT website (www.catestonline.org). The CBQC experts believe that the CAT is a well-established, easy-to-use tool for the management of patients with COPD and that it is a useful outcome measure for the assessment of quality of life and disease burden in clinical trials.

Read More

The COPD Foundation Welcomes Olympus to Our Corporate Partner Program

December 03, 2019

Washington, DC - Dec. 3, 2019 – The COPD Foundation is pleased to announce that Olympus Medical Systems Group, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, recently joined as a member of the Corporate Partner Program. The COPD Foundation began the corporate partners program in 2016 as a way to standardize the way in which we interact with external, corporate stakeholders with the shared mission of accelerating research, pioneering research and improving the lives of all individuals affected by chronic obstructive pulmonary disease (COPD).

In December 2018, Olympus received approval from the Federal Drug Administration (FDA) for its Spiration Valve® System (SVS), intended for patients with severe emphysema. The valves are placed bronchoscopically in targeted airways of the lungs and, once in place, redirect air from diseased parts of the lungs to healthier areas, allowing the healthier lung tissue to expand and function more efficiently.

The primary results of the randomized clinical trial, entitled “Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve® System (EMPROVE): A Multicenter, Open-Label, Randomized, Controlled Trial” were measured six months after treatment and showed that SVS brings many benefits to patients, including improved lung function, target lobe volume reduction, decreased hyperinflation, a reduction in shortness of breath and an overall improvement in their quality of life. The study continued to follow patients and has now showed that improvement in measures important to patients such as lung function, shortness of breath and quality of life are durable through twelve months.

Read More

New Research Gives Hope for Slowing Progression and Mortality of Fourth Leading Cause of Death

November 13, 2019

WASHINGTON, DC--Research published yesterday suggests that we may be able to finally find a way to slow disease progression and provide preventative measures for the first time to individuals at risk of developing the 4th leading cause of death in the United States—chronic obstructive pulmonary disease (COPD).

In a bold proposal that challenges decades-old criteria, the new research analysis—published in the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation—proposes to expand the criteria by which smokers are diagnosed with COPD which affects an estimated 30 million individuals in the U.S. alone (15 million diagnosed, another 15 million estimated to be undiagnosed with the disease).

Using the new criteria proposed in the published article would enable treatment to be provided earlier to slow or halt disease progression before disability or irreversible lung structural changes occurs. This new proposal comes from the COPD Genetic Epidemiology (COPDGene) study—a 21-center study of 10,000 individuals supported by the National Institutes of Health and begun in 2007.

Read More

Ruth Tal-Singer is Joining the COPD Foundation Team

October 25, 2019

WASHINGTON, DC, October 25, 2019— The COPD Foundation is pleased to announce that Ruth Tal-Singer, Ph.D., has joined the Foundation as a consultant in the role of Chief Scientific Strategy Officer. Ms. Tal-Singer is an internationally recognized expert and leader in the field of respiratory care. Her appointment became official as of October 21, 2019.

Prior to joining the COPD Foundation, Ms. Tal-Singer was Vice President of Medical Innovation (Galaxy) R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals. During her career with GSK, she led many projects that resulted in new and innovative treatments for COPD.

“We are all thrilled that Ruth Tal-Singer will be joining the COPD Foundation. Ruth brings a vast experience in COPD research and development. Beyond her scientific expertise she has a deep commitment to the mission of the COPD Foundation- to prevent and cure chronic obstructive pulmonary disease (COPD) and to improve the lives of all people affected by COPD. Her recruitment represents a major step forward for the Foundation,” said Dr. Byron Thomashow, Chief Medical Officer at the COPD Foundation.

Read More

The COPD Foundation Announces the Launch of Our New Patient-Focused Mobile App

October 21, 2019

Washington, DC—October 21, 2019 - The COPD Foundation is pleased to announce that we have launched a new version of our popular Pocket Consultant Guide (PCG) mobile app featuring a track for patients and caregivers. The PCG was originally designed as a convenient reference card for healthcare providers. The mobile version was launched in 2013 and updated in 2018. Immediately after the updated app was launched, our team began thinking of ways to improve the patient experience through a mobile app.

"Since 2007 the COPD Foundation has distributed more than 800,000 pocket consultant cards to providers around the country in hope of improving COPD care. Several years ago, the Foundation updated our free app providing a more interactive service including inhaler videos. We believe the launch of the newest version represents another important step to improving care. This new version includes a patient track with an interactive daily action plan, activity monitoring, and exercise videos. Together we can make a difference!" – Dr. Byron Thomashow, Chief Medical Officer, COPD Foundation

The newest version of the app, now available on the App Store and Google Play, has several exciting new features, including the introduction of a patient and caregiver track designed to improve disease management and communication with a patient’s healthcare team. Some of the features of the patient track include:

Read More

Community-Acquired Pneumonia (CAP) Causes Significant Burden for Vulnerable COPD Population

February 05, 2019

Study shows individuals with COPD-CAP often require weeks to recover, resulting in missed work and participation in usual activities.

Washington, DC – February 4, 2019 – According to a new study posted online in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation and conducted by the COPD Foundation in collaboration with and funded by Pfizer Inc., community-acquired pneumonia (CAP), which carries a high morbidity and economic burden worldwide, is even more physically and economically devastating to the vulnerable population of individuals with chronic obstructive pulmonary disease (COPD). CAP is a common but serious lung infection that can be caused by bacterial or viral pathogens including Streptococcus pneumoniae, influenza or rhinovirus.

Read More

COPD Foundation Examines the Burden of COPD in the United States in Landmark Effort

November 30, 2018

COPD across America – How is your state is doing?

WASHINGTON, D.C. – November 30, 2018 – The COPD Foundation is pleased to announce the results of a landmark effort that examines the burden of COPD across America. The “COPD in the United States” project looks at COPD at the state level, identifying differences across states, regions and data points, to inform public health and policy decision-making.

COPD affects an estimated 30 million Americans but, up until now, little has been known about how one state compares to another. With the addition in 2011 of a COPD question to the Centers for Disease Control and Prevention’s Behavioral Risk Factor Surveillance System (BRFSS), the nation’s largest public health survey, more actionable information has been collected. State level data also exists to highlight the healthcare services individuals with COPD use, other conditions people with COPD may have and how different groups of people with COPD are affected.

Just collecting data isn’t enough, though, as it often sits in fragmented databases, is not analyzed or available for advocates, public health and policy decision-makers. With this project, the COPD Foundation aims to change that.

Read More

COPD Foundation Launches New App to Improve Quality of Care For COPD Patients

November 05, 2018

COPD Pocket Consultant Guide App now available for both iOS and Android

WASHINGTON, D.C. - November 5, 2018 –The COPD Foundation is excited to announce the launch of the COPD Pocket Consultant Guide (PCG) app for healthcare providers. The app, designed to support the treatment and management of COPD, is now available for both iOS and Android. To download the new COPD PCG app, click here.

Key features of the COPD PCG app include an updated therapy chart including the latest medications for COPD, inhaler instruction videos, depression and anxiety screeners, links to COPD Foundation resources and more.

Additional features, such as the Fletcher-Peto Impact of Smoking graph and lung volume reduction options, are included in the app as well as links to PRAXIS (the COPD Foundation’s online hub for healthcare providers), the Journal of the COPD Foundation and the National Heart, Lung and Blood Institute’s COPD National Action Plan.

Read More

FDA Approves Zephyr Endobronchial Valve For Treating Severe Emphysema

June 29, 2018

REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for treating patients with severe emphysema, a progressive and life-threatening form of chronic obstructive pulmonary disease (COPD).

The approval is based on positive clinical data from the pivotal LIBERATE Study and two other multicenter randomized control trials. In the LIBERATE study, patients treated with Zephyr Valves were able to breathe easier, be more active and energetic, be less short of breath, and enjoy a significantly improved quality of life compared to patients who received medical management alone.

As stated in the Summary of Safety and Effectiveness Data, the FDA granted the Zephyr Valve an expedited review because it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers significant clinically meaningful advantage over the current standard of care and therefore its availability is also in the best interest of patients.” “Zephyr Valves are a major step forward in treating severe emphysema patients who consistently feel short of breath despite all the medications we can offer. I have seen Zephyr Valve-treated patients getting back to a more active life doing the things they enjoy. As a physician, it is very gratifying to have a new treatment that can restore a patient’s confidence and change their life for the long term,” said Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, and lead investigator for the LIBERATE Study.

Read More

Tags: Zephyr® Endobronchial Valve System

1 2 3 4 5 6